DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of ...

-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...